<DOC>
	<DOCNO>NCT01414205</DOCNO>
	<brief_summary>This open-label , multicenter , randomize study compare efficacy , safety pharmacokinetics obinutuzumab ( RO5072759 ; GA101 ) 1000 mg versus 2000 mg participant previously untreated CLL . Participants randomize receive maximum 8 cycle ( 28-day cycle ) obinutuzumab ( 1000 mg intravenous [ IV ] infusion , Days 1 , 8 15 Cycle 1 Day 1 subsequent cycle 8 cycle maximum 8 cycle obinutuzumab ( 2000 mg IV infusion , Days 1 , 8 15 Cycle 1 Day 1 subsequent cycle 8 cycle .</brief_summary>
	<brief_title>A Study Comparing Obinutuzumab ( RO5072759 ; GA101 ) 1000 Milligram ( mg ) Versus 2000 mg Participants With Previously Untreated Chronic Lymphocytic Leukemia ( CLL ) ( GAGE )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<criteria>Confirmed diagnosis CD20positive Bcell CLL ( per International Workshop Chronic Lymphocytic Leukemia [ IWCLL ] guideline ) Rai Stage III/IV Binet Stage C disease , Rai Stage I/II Binet Stage B disease require treatment accord IWCLL guideline No previous treatment CLL chemotherapy , radiotherapy immunotherapy ; previous rituximab treatment autoimmune hemolytic anemia ( AIHA ) idiopathic thrombocytopenic purpura ( ITP ) ; prior use steroid AIHA ITP allow Eastern Cooperative Oncology Group performance status 0 , 1 2 Confirmed diagnosis Transformation CLL aggressive Bcell malignancy History severe allergic anaphylactic reaction monoclonal antibody therapy Evidence severe , uncontrolled concomitant disease Known active infection major episode infection require treatment IV antibiotic hospitalization within 4 week start Cycle 1 Seropositive human immunodeficiency virus ( HIV ) Positive chronic hepatitis B infection ( define positive hepatitis B surface antigen [ HBsAg ] serology ) Positive hepatitis C ( hepatitis C virus [ HCV ] antibody serology test ) Pregnant lactate woman Concurrent ( within 7 day prior first dose study treatment ) systemic corticosteroid use , except lowdose corticosteroid therapy use treat chronic medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>